You just read:

Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention

News provided by

Janssen R&D Ireland

25 Sep, 2013, 10:00 BST